Archemix Corp.
Records under this name other than the patents Archemix Corp. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,252,913 | Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics Formerly held In force · High confidence | In force | High confidence | |
| US 8,236,773 | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders Formerly held Term ended Term ended Nov 11, 2026 · Medium confidence | Term ended | Term ended Nov 11, 2026 | Medium confidence |
| US 10,100,316 | Aptamers comprising CPG motifs Term ended Term ended Jul 26, 2025 · From the USPTO record | Term ended | Term ended Jul 26, 2025 | From the USPTO record |
| US 11,913,000 | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders Formerly held Term ended Term ended Apr 25, 2025 · Medium confidence | Term ended | Term ended Apr 25, 2025 | Medium confidence |
| US 7,538,211 | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders Formerly held Term ended Term ended Feb 14, 2025 · High confidence | Term ended | Term ended Feb 14, 2025 | High confidence |
| US 7,579,456 | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders Formerly held Term ended Ended no later than Feb 14, 2025 · Low confidence | Term ended | Ended no later than Feb 14, 2025 | Low confidence |
| US 7,803,931 | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders Formerly held Term ended Term ended Feb 14, 2025 · Medium confidence | Term ended | Term ended Feb 14, 2025 | Medium confidence |
| US 8,436,164 | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders Formerly held Term ended Term ended Feb 14, 2025 · High confidence | Term ended | Term ended Feb 14, 2025 | High confidence |
| US 9,617,546 | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders Formerly held Term ended Ended no later than Feb 14, 2025 · Low confidence | Term ended | Ended no later than Feb 14, 2025 | Low confidence |
| US 10,947,544 | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders Formerly held Term ended Term ended Feb 14, 2025 · Medium confidence | Term ended | Term ended Feb 14, 2025 | Medium confidence |